How to Reverse Fatty Liver: What the Guidelines Say Works

TL;DR

• Fatty liver can often improve. Guidelines say losing at least 5% of your body weight reduces liver fat, 7–10% improves inflammation, and 10% or more can improve scarring.
• The core plan: a Mediterranean-style diet with fewer sugary drinks and ultra-processed foods, about 150 minutes of activity a week, little or no alcohol, and good control of blood sugar, cholesterol and blood pressure.
• Progress is tracked with ALT, FIB-4 and FibroScan. Two medicines are approved for MASH with moderate to advanced scarring, not for simple fatty liver.

Yes, fatty liver can often be reversed, or at least greatly improved, especially when it’s caught before significant scarring. The single most powerful lever is steady, sustained weight loss if you carry extra weight, backed by better food choices, regular movement and cutting back on alcohol.

What “reversal” means depends on how far the disease has gone. Liver fat responds relatively quickly. Inflammation takes more. Scarring (fibrosis) is the slowest to change and needs the biggest, longest-lasting effort. This guide walks through what the two main guidelines for MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) recommend: the American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance and the 2024 European EASL–EASD–EASO guideline.

What Does “Reversing” Fatty Liver Actually Mean?

Fatty liver isn’t one thing. It’s a spectrum, and each layer responds differently.

Layer	What’s happening in the liver	What tends to improve it	How it’s usually checked
Steatosis (simple fatty liver)	Extra fat stored in liver cells	Modest weight loss (about 5%), less sugar and alcohol, more activity	Ultrasound, FibroScan CAP, MRI
Steatohepatitis (MASH, formerly NASH)	Fat plus inflammation and liver cell injury	Larger weight loss (about 7–10%), same habits held longer	Blood tests hint at it; biopsy confirms it
Fibrosis (scarring, stages F0–F4)	Scar tissue building up after long-term injury	10% or more weight loss, sustained; medicines for some	FIB-4, FibroScan stiffness, sometimes biopsy
Cirrhosis (F4)	Advanced scarring that changes liver structure	Goal shifts to preventing complications	Specialist care

Many people with fatty liver have little or no scarring, and that’s the most responsive stage. If you haven’t been told your fibrosis stage, that’s one of the most useful things to ask your doctor, because it shapes how aggressive the plan needs to be. If you’re not sure what the new names mean, see our guide to MASLD vs NAFLD.

How Much Weight Do You Need to Lose to Reverse Fatty Liver?

Weight loss is the best-studied treatment for fatty liver, and the guidelines are specific about targets. The 2024 European guideline says that in adults with MASLD and overweight, weight loss should aim for a sustained reduction of at least 5% to reduce liver fat, 7–10% to improve liver inflammation, and 10% or more to improve fibrosis.

The AASLD guidance puts it slightly differently: losing 3–5% of body weight improves steatosis, but greater weight loss (more than 10%) is generally needed to improve MASH and fibrosis. NIDDK gives the same picture: at least 3–5% to reduce liver fat, and up to 7–10% to reduce inflammation and fibrosis.

Here’s what those percentages look like in real numbers:

Starting weight	5% (liver fat)	7% (inflammation)	10% (fibrosis)
160 lb (73 kg)	8 lb (3.6 kg)	11 lb (5.1 kg)	16 lb (7.3 kg)
200 lb (91 kg)	10 lb (4.5 kg)	14 lb (6.4 kg)	20 lb (9.1 kg)
240 lb (109 kg)	12 lb (5.4 kg)	17 lb (7.6 kg)	24 lb (10.9 kg)

Some of the clearest evidence comes from a 2015 study in Gastroenterology that followed 293 people with biopsy-proven NASH through 52 weeks of lifestyle change. Among those who lost 10% or more of their weight, 90% had resolution of NASH and 45% had regression of fibrosis. The study also shows how hard this is: only 30% of participants reached even 5% weight loss.

Two practical points matter here:

• Slow and steady is the goal. NIDDK notes that doctors recommend losing weight gradually, because rapid weight loss and malnutrition can make liver disease worse. Crash diets aren’t a shortcut.
• “Sustained” is the key word. The benefit comes from keeping the weight off. A plan you can live with beats a plan that works for six weeks.

What Should You Eat to Reverse Fatty Liver?

No single food reverses fatty liver. What matters is the overall pattern, and whether it helps you eat a little less without feeling deprived. The European guideline recommends improving diet quality toward a Mediterranean-style pattern, limiting ultra-processed foods (which tend to be rich in sugar and saturated fat), and avoiding sugar-sweetened beverages.

In practice, that means:

• Build meals around plants. Vegetables, legumes, whole grains, fruit, nuts and seeds.
• Pick better fats. NIDDK advises replacing saturated and trans fats with unsaturated fats, especially omega-3s. Olive oil, nuts and oily fish fit well.
• Cut sugary drinks first. The AASLD notes that excess fructose in particular raises the risk of MASLD, MASH and advanced fibrosis, independent of calories. Soda, sweet tea, sports drinks and juice are the easiest place to start.
• Go easy on refined starch. White bread, pastries and big portions of white rice add calories fast without much fiber.
• Coffee is fine, and may help. The AASLD guidance says drinking 3 or more cups a day could be recommended in the absence of other reasons to avoid it, based on a lower risk of MASLD and fibrosis.

For the full picture, including what a day of eating looks like, see our fatty liver diet guide.

How Much Exercise Helps Fatty Liver?

Exercise helps the liver in two ways: it supports weight loss, and it reduces liver fat on its own. NIDDK notes that physical activity alone, even without weight loss, is beneficial.

The targets:

• European guideline: more than 150 minutes a week of moderate activity, or 75 minutes a week of vigorous activity.
• AASLD: regular moderate exercise at least 5 times a week for a total of 150 minutes, or increasing your activity by more than 60 minutes a week, can prevent or improve MASLD.

Moderate means brisk walking, cycling or swimming at a pace where you can talk but not sing. If 150 minutes sounds like a lot, the AASLD’s second option is a useful starting point: add an hour a week to whatever you do now, then build.

Do You Have to Stop Drinking Alcohol?

It depends on your fibrosis stage, but less is always better for a fatty liver.

• The AASLD says people with MASLD and clinically significant fibrosis (F2 or higher) should abstain from alcohol completely.
• The European guideline says all alcohol should be stopped completely and permanently with advanced fibrosis or cirrhosis, and discourages drinking for people with steatotic liver disease, especially those who drink moderate or high amounts.
• Even moderate drinking is linked to a higher chance of advanced fibrosis, particularly in people with obesity or type 2 diabetes, according to the AASLD.

If you don’t know your fibrosis stage, treat alcohol as something to cut sharply until you do. Our article on whether alcohol is safe with fatty liver goes deeper.

Why Blood Sugar, Cholesterol and Blood Pressure Matter

Fatty liver travels with type 2 diabetes, high triglycerides, low HDL and high blood pressure. That’s why the new MASLD definition is built around these risk factors. It also matters for survival: according to the AASLD, the most common causes of death in people with fatty liver are cardiovascular disease and non-liver cancers, followed by liver disease. Treating the whole metabolic picture protects your heart and your liver at the same time.

What the guidelines say about common medicines:

• Statins are safe in fatty liver across the disease spectrum, including advanced disease, and reduce cardiovascular risk (AASLD). The European guideline says they can be used in people with compensated cirrhosis too. Fatty liver is not a reason to skip a statin you need.
• GLP-1 medicines (such as semaglutide) are safe to use in MASH, including compensated cirrhosis, and should be used for their approved uses in type 2 diabetes and obesity (European guideline).
• Pioglitazone, a diabetes medicine, led to MASH resolution in 47% of trial participants versus 21% on placebo, as summarized in the AASLD guidance.
• SGLT2 inhibitors appear to reduce liver fat, though their effect on liver tissue is less well defined (AASLD).

If you have diabetes, ask whether your current treatment is also a good fit for your liver.

How Long Does It Take to Reverse Fatty Liver?

This is the question everyone asks, and the honest answer is that no guideline gives a timeline, and your doctor can’t promise one either. What the research does show:

• Liver fat tends to respond first. It tracks closely with weight and diet, so it’s usually the earliest thing to improve.
• Inflammation and scarring take longer. The key studies measured results after 52 weeks of lifestyle change, 72 weeks of semaglutide in the ESSENCE trial, and one year after bariatric surgery. Changes in fibrosis are typically judged over a year or more.
• Improvement isn’t guaranteed. Even in trials, some people with good weight loss don’t see fibrosis regress.

The encouraging part: the European guideline notes that regression of fibrosis is associated with a lower risk of liver-related complications. Every step back from advanced scarring counts.

How Do Doctors Measure Progress?

You can’t feel liver fat going down, so progress is measured with tests. Each one answers a different question.

Test	What it tells you	What to keep in mind
ALT (blood)	Ongoing liver cell irritation	ALT normalization can predict MASH resolution (AASLD), but normal ALT doesn’t rule out scarring
FIB-4 (calculated from age, AST, ALT and platelets)	Risk of advanced fibrosis	Below 1.3 is low risk; above 2.67 is high risk. Moving between categories can signal change
FibroScan stiffness (kPa)	Liver stiffness, a stand-in for scarring	Under 8 kPa can rule out advanced fibrosis; over 12 kPa suggests it’s likely
FibroScan CAP	A rough read on liver fat	Doesn’t accurately quantify or monitor changes in liver fat, per the AASLD
MRI-PDFF	A precise measure of liver fat	Used more in specialist centers and research
Liver biopsy	Direct look at fat, inflammation and scarring	Rarely needed; used when results are unclear

How often? The AASLD suggests people with 1–2 metabolic risk factors and no diabetes can have FIB-4 rechecked every 2–3 years, while people with prediabetes, type 2 diabetes or 2 or more risk factors should be rechecked more often, for example every 1–2 years. For a closer look at the blood tests, read ALT and AST levels in fatty liver.

When Do Medicines Come In?

For most people with fatty liver, lifestyle change is the treatment. Medicines enter the picture when there is MASH with meaningful scarring. As of September 2026, two medicines have US approval for this:

• Resmetirom (Rezdiffra) was approved by the FDA on March 14, 2024, for adults with noncirrhotic MASH (then called NASH) with moderate to advanced fibrosis, used along with diet and exercise. It was an accelerated approval, with continued approval depending on confirmatory trials. The FDA noted possible liver toxicity, gallbladder-related side effects and interactions with statins and other drugs, and that it should be avoided in decompensated cirrhosis.
• Semaglutide (Wegovy) 2.4 mg received FDA accelerated approval on August 15, 2025, for adults with noncirrhotic MASH with moderate to advanced fibrosis, to be used with a reduced-calorie diet and increased physical activity. In November 2025, the AASLD published updated guidance on using it.

Both are for stage F2–F3 fibrosis without cirrhosis. Neither is approved for simple fatty liver, and neither replaces diet and exercise. For people with severe obesity, bariatric surgery is another option: the AASLD guidance cites resolution of NASH without worsening fibrosis in 80% of patients one year after surgery, maintained at five years.

If your FIB-4 or FibroScan suggests significant scarring, ask whether you should see a hepatologist to discuss these options.

A Practical Way to Start

Big goals work best when broken into small, specific habits. Here’s one way to start:

1. Know your numbers. Ask for your ALT, AST, platelets and FIB-4 score, and whether a FibroScan makes sense. Write down your starting weight and waist.
2. Set a first target of 5%. It’s achievable, and it’s the level guidelines link to less liver fat.
3. Swap your drinks. Replace soda, juice and sweet coffee drinks with water, unsweetened tea or black coffee.
4. Change one meal at a time. Start with the meal you eat out most or the one heaviest in refined starch. Our list of best foods for fatty liver gives you swaps.
5. Add movement you’ll repeat. A 30-minute walk five days a week gets you to 150 minutes.
6. Cut alcohol sharply, and to zero if you have significant fibrosis.
7. Track honestly for a few weeks. It’s easy to underestimate sugar and portion sizes. An app like Liverly can scan a meal and give it a Liver Score, which makes the hidden sugar and saturated fat easier to spot.
8. Recheck with your doctor at the interval they recommend, and adjust.

One important exception: if you’ve been diagnosed with cirrhosis, nutrition advice changes. Most people then need more protein and should avoid long fasts, and weight loss has to be supervised. See our cirrhosis diet guide and follow your care team.

The Bottom Line

Fatty liver is one of the more responsive chronic conditions, especially before scarring sets in. Losing at least 5% of your body weight reduces liver fat, 7–10% improves inflammation, and 10% or more gives fibrosis the best chance to regress. A Mediterranean-style diet with few sugary drinks, around 150 minutes of weekly activity, little or no alcohol, and good control of blood sugar and cholesterol form the foundation. Medicines now exist for MASH with moderate to advanced scarring, but they work alongside these habits, not instead of them. Know your fibrosis stage, set realistic targets, and let your tests, not the calendar, tell you how your liver is responding.

Sources

• EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD: Executive Summary (2024)
• AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (Rinella et al., Hepatology 2023)
• Vilar-Gomez et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis (Gastroenterology 2015)
• FDA: FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease (March 2024)
• Novo Nordisk: Wegovy approved by FDA for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (August 2025)

This article is for informational purposes only and is not medical advice. Talk to your doctor or hepatologist about your specific situation.